Cargando…
ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report
SCLC transformation is a phenomenon that is rarely described in ALK-rearranged cancers after treatment with ALK tyrosine kinase inhibitors, and it is exceedingly rare after lorlatinib use. We report the first case of a patient with an ALK-EML4 rearrangement who was resistant to lorlatinib simply due...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941368/ https://www.ncbi.nlm.nih.gov/pubmed/36824291 http://dx.doi.org/10.1016/j.jtocrr.2023.100464 |
_version_ | 1784891271581532160 |
---|---|
author | Li, Huihui Song, Tianqi Xu, Xiaoling |
author_facet | Li, Huihui Song, Tianqi Xu, Xiaoling |
author_sort | Li, Huihui |
collection | PubMed |
description | SCLC transformation is a phenomenon that is rarely described in ALK-rearranged cancers after treatment with ALK tyrosine kinase inhibitors, and it is exceedingly rare after lorlatinib use. We report the first case of a patient with an ALK-EML4 rearrangement who was resistant to lorlatinib simply due to transformation to SCLC and rapidly achieved partial response after traditional etoposide combined with cisplatin therapy. In addition, we provide a fishplot that visualizes tumor evolution on the basis of next-generation sequencing, which may predict small cell transformation and facilitate early treatment. |
format | Online Article Text |
id | pubmed-9941368 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-99413682023-02-22 ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report Li, Huihui Song, Tianqi Xu, Xiaoling JTO Clin Res Rep Case Report SCLC transformation is a phenomenon that is rarely described in ALK-rearranged cancers after treatment with ALK tyrosine kinase inhibitors, and it is exceedingly rare after lorlatinib use. We report the first case of a patient with an ALK-EML4 rearrangement who was resistant to lorlatinib simply due to transformation to SCLC and rapidly achieved partial response after traditional etoposide combined with cisplatin therapy. In addition, we provide a fishplot that visualizes tumor evolution on the basis of next-generation sequencing, which may predict small cell transformation and facilitate early treatment. Elsevier 2023-01-20 /pmc/articles/PMC9941368/ /pubmed/36824291 http://dx.doi.org/10.1016/j.jtocrr.2023.100464 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Case Report Li, Huihui Song, Tianqi Xu, Xiaoling ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report |
title | ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report |
title_full | ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report |
title_fullStr | ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report |
title_full_unstemmed | ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report |
title_short | ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report |
title_sort | alk-positive adenocarcinoma after acquired resistance to lorlatinib and transformation to sclc: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941368/ https://www.ncbi.nlm.nih.gov/pubmed/36824291 http://dx.doi.org/10.1016/j.jtocrr.2023.100464 |
work_keys_str_mv | AT lihuihui alkpositiveadenocarcinomaafteracquiredresistancetolorlatinibandtransformationtosclcacasereport AT songtianqi alkpositiveadenocarcinomaafteracquiredresistancetolorlatinibandtransformationtosclcacasereport AT xuxiaoling alkpositiveadenocarcinomaafteracquiredresistancetolorlatinibandtransformationtosclcacasereport |